Pathways of chemical degradation of polypeptide antibiotic bacitracin

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 11, 2006, Pages 2160-2167

  Pavli, Viljem ^a   Kmetec, Vojko ^b  

^a KRKA D D   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Bacitracin; Deamidation; Degradation product; Monolithic silica reversed phase column; Oxidation; Stability

Indexed keywords

BACITRACIN; POLYPEPTIDE ANTIBIOTIC AGENT;

ALKALINITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DEAMINATION; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG INHIBITION; DRUG OXIDATION; DRUG STABILITY; FAST ATOM BOMBARDMENT MASS SPECTROMETRY; IC 50; MASS SPECTROMETRY; MICROCOCCUS LUTEUS; NONHUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

AMIDES; ANTI-BACTERIAL AGENTS; BACITRACIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FERMENTATION; HYDROCHLORIC ACID; HYDROGEN PEROXIDE; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; MICROCOCCUS LUTEUS; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PEPTIDES; TEMPERATURE;

EID: 33750612344     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.2160     Document Type: Article

References (27)

1. Brewer G. A., "Analytical Profiles of Drug Substances," Vol. 9, ed. by Florey F., Academic Press, New York, 1980, pp. 1-69.
2. Frøyshov Ø., "Biotechnology of Industrial Antibiotics," ed. by Vandamme E. J., Marcel Dekker, New York, 1983, pp. 665-694.
3. USP 27th and NF 22, United States Pharmacopeial Convention, ed. by Inc. 1260 Twinbrook Parkway, Rockville, 2003, pp. 203-206.
4. Lester A. M., "Foye's Principles of Medicinal Chemistry," 5th ed., ed. by Williams D. A., Lemke T. L., Lippincott Williams & Wilkins, Baltimore, 2002, pp. 861-864.
5. European Pharmacopeia, 5th ed., ed. by Council of Europe, 67075 Strasbourg, Cedex France, 2004, pp. 1045-1050.
6. Ikai Y., Oka H., Hayakawa J., Matsumoto M., Saito M., Harada K.-I., Mayumi T., Suzuki M., J. Antibiot., 48, 233-242 (1995).
7. Ikai Y., Oka H., Hayakawa J., Harada K.-I., Suzuki M., J. Antibiot., 45, 1325-1334 (1992).
8. Pavli V., Sokolić M., J. Liq. Chromatogr., 13, 303-318 (1990).
9. Ming L.-J., Epperson J. D., J. Inorg. Biochem., 91, 46-58 (2002).
10. Orwa J. A., Zels K., Roets E., Hoogmartens J., PharmEuropa, 13, 692-696 (2001).
11. Kresken M., Hafner D., Infection, 27, S2-S8 (1999).
12. Doern G. V., Heilmann K. P., Huynh H. K., Rhomberg P. R., Coffman S. L., Brueggmann A. B., Antimicrob. Agents Chemother., 45, 1721-1729 (2005).
13. Zasloff M., Nature (London), 415, 389-395 (2002).
14. Pesuna P. J., Bhalla H. L., Gopal N. G. S., Indian J. Pharm. Sci., 1984, 54 (1984).
15. Trissel L. A., "Trissel's Stability of Compounded Formulations," ed. by Trissel L. A., American Pharmaceutical Association, Washington, D.C., 1996, pp. 25-26.
16. El-Bayoumy T., J. Drug Res. Egypt, 17, 153-161 (1987).
17. Souney P. F., Braun L., Steele L., Fanikos J., Am. J. Hosp. Pharm., 44, 1125-1126 (1987).
18. Osborn E., Baum J. L., Ernst C., Koch P., Am. J. Ophthalmol., 82, 775-780 (1976).
19. Newton G. G. F., Abraham E. P., Florey H. W., Smith N., Brit. J. Pharmacol., 6, 417-429 (1951).
20. Konigsberg W., Craig L. C., Org. Chemistry, 27, 934-938 (1962).
21. Pavli V., Kmetec V., J. Pharm. Biomed. Anal., 36, 257-264 (2004).
22. Pavli V., Kmetec V., J. Liq. Chromatogr. Relat. Technol., 27, 2381-2396 (2004).
23. Lubda D., Cabrera K., Kraas W., Schaefer C., Cunningham D., LC-GC, 19, 1186-1191 (2001).
24. Tsuji K., Robertson H., J. Chromatogr., 112, 663-672 (1975).
25. Pavli V., Kmetec V., J. Biomed. Anal., 24, 977-982 (2001).
26. Dibiase M. D., Kottke M. K., "Drug Stability. Principles and Practices," 3rd ed., Revised and expanded, ed. by Carstensen J. T., Rhodes C. T., Marcel Dekker, New York, 2000, pp. 553-578.
27. Li B., Gorman E. M., Moore K. D., Williams T., Schowen R. L., Topp E. M., Borchardt R. T., J. Pharm. Sci., 94, 666-675 (2005).